Glycotope GmbH
Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies (news with additional features)
Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies – GATTO Study Extension to Evaluate Gatipotuzumab and Tomuzotuximab or marketed anti-EGFR Monoclonal Antibody Drugs in refractory metastatic solid tumors – First patient enrolled in extension of international, multicenter study – First study to evaluate the potential of the combination of anti-EGFR and anti-TAMuc1 targeting
The phase Ib trial expansion will evaluate the feasibility, safety and efficacy of the combination of Gatipotuzumab with either Tomuzotuximab or a marketed anti EGFR antibody in patients with solid tumors such as metastatic colorectal, lung, breast and head and neck cancers with measurable disease after failure of standard treatment options. GATTO is an international, multicenter phase Ib trial enrolling patients in Germany, Italy and Spain. The combination of Gatipotuzumab with Tomuzotuximab or a marketed anti EGFR antibodies is based on a strong preclinical rationale and preliminary clinical evidence from the first 20 patients enrolled in the study. “We are pleased to have enrolled the first patient in this innovative and interesting trial expansion which will enable us to build on the preliminary clinical evidence from the first 20 patients enrolled in the study. We are excited to learn more about Gatipotuzumab’s efficacy when combined with anti EGFR antibodies,” said Dr. Alfredo Zurlo, MD, external Medical Head of Glycotope GmbH. “The trial aims to confirm in selected cancer patients the preclinical synergy observed in combining anti-EGFR and anti TA-MUC1 targeting.” “The GATTO trial extension further highlights the potential and wide applicability of gatipotuzumab” said Henner Kollenberg, Managing Director of Glycotope GmbH. “We believe the versatility of our technology platform combined with our world-leading glycobiology expertise and clinical experience in oncology and primarily immuno-oncology leaves us well placed to further strengthen our position in the field.” The GATTO study has been registered with the European Medical Agency under the EudraCT number 2017-001609-33 About Gatipotuzumab About Tomuzotuximab About Glycotope Glycotope’s GlycoExpress(R) (GEX(R)) platform allows glyco-optimization and high yield production of a variety of fully human glycosylated biopharmaceuticals such as antibodies, glycoprotein hormones, coagulation factors and cytokines, and by using a toolbox of glyco-engineered proprietary human cell lines that allow for optimization of a whole series of different determining sugars. In addition, the GEX(R) platform can be used for in process glycosylation control. Visit http://www.glycotope.com/. Contact: Consilium Strategic Communications End of Media Release Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=PIVRLJHCET Document title: Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies Issuer: Glycotope GmbH Key word(s): Research/Technology
25.03.2019 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG. |